UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis

The New England journal of medicine, 2011-09, Vol.365 (12), p.1079-1087

2011

Volltextzugriff (PDF)

An exploratory study investigating biomarkers associated with autoimmune pulmonary alveolar proteinosis (aPAP)

Scientific reports, 2022-05, Vol.12 (1), p.8708-8708, Article 8708

2022

Volltextzugriff (PDF)

Transcriptomic characterization of the human segmental endotoxin challenge model

Scientific reports, 2024-01, Vol.14 (1), p.1721-1721, Article 1721

2024

Volltextzugriff (PDF)

Baseline characteristics from a 3-year longitudinal study to phenotype subjects with COPD: the FOOTPRINTS study

Respiratory research, 2023-11, Vol.24 (1), p.1-290, Article 290

2023

Volltextzugriff (PDF)

Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis

ERJ open research, 2020-10, Vol.6 (4), p.429

2020

Volltextzugriff (PDF)

Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment

Pulmonary pharmacology & therapeutics, 2015-06, Vol.32, p.37-44

2015

Volltextzugriff (PDF)

FOOTPRINTS study protocol: rationale and methodology of a 3-year longitudinal observational study to phenotype patients with COPD

BMJ open, 2021-03, Vol.11 (3), p.e042526-e042526

2021

Volltextzugriff (PDF)

A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf

ERJ open research, 2023-05, Vol.9 (3), p.633

2023

Volltextzugriff (PDF)

An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CFTM 1

ERJ open research, 2020-12, Vol.6 (4)

2020

Volltextzugriff (PDF)

Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia

The Journal of immunology (1950), 2002-04, Vol.168 (8), p.4070-4077

2002

Volltextzugriff (PDF)

Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia

Blood, 2003-06, Vol.101 (11), p.4446-4448

2003

Volltextzugriff (PDF)

TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial

Thorax, 2023-08, Vol.78 (8), p.816

2023

Volltextzugriff (PDF)

Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study

The European respiratory journal, 2022-02, Vol.59 (2), p.2100746

2022

Volltextzugriff (PDF)

The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers

Pulmonary pharmacology & therapeutics, 2023-10, Vol.82, p.102246-102246, Article 102246

2023

Volltextzugriff (PDF)

FEV1 recovery following methacholine challenge in asthma: Variability and comparison of methods

Pulmonary pharmacology & therapeutics, 2020-02, Vol.60, p.101876-101876, Article 101876

2020

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well‐Controlled Asthma

Journal of clinical pharmacology, 2017-11, Vol.57 (11), p.1444-1453

2017

Volltextzugriff (PDF)

A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma

Allergy and asthma proceedings, 2017-03, Vol.38 (2), p.157

2017

Volltextzugriff (PDF)

COPDGene ® 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary diseases, 2019-01, Vol.6 (5), p.384-399

2019

Volltextzugriff (PDF)

Anticipated responses to a hypothetical minimum price for cigarettes and roll-your-own tobacco: an online cross-sectional survey with cigarette smokers and ex-smokers in the UK

BMJ open, 2021-03, Vol.11 (3), p.e042724-e042724

2021

Volltextzugriff (PDF)

FEV 1 recovery following methacholine challenge in asthma: Variability and comparison of methods

Pulmonary pharmacology & therapeutics, 2020-02, Vol.60, p.101876

2020

Volltextzugriff (PDF)

An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CF TM 1

ERJ open research, 2020-10, Vol.6 (4), p.395

2020

Volltextzugriff (PDF)

P38 mitogen activated protein kinase is involved in the downregulation of granulocyte CXC chemokine receptors 1 and 2 during human endotoxemia

Journal of Clinical Immunology, 2004-01, Vol.24 (1), p.37-41

2004

Volltextzugriff (PDF)

Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis

Journal of allergy and clinical immunology, 2014-02, Vol.133 (2), p.414-419.e8

2014

Volltextzugriff (PDF)

Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist Bl 671800 in patients with seasonal allergic rhinitis

Journal of allergy and clinical immunology, 2014, Vol.133 (2), p.414-419

2014

Volltextzugriff (PDF)

Drug-induced hypothyroidism: The thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides

Clinical pharmacology and therapeutics, 1992-01, Vol.51 (1), p.56-67

1992

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(22)
Life Sciences & Biomedicine
(21)
Humans
(18)
Male
(11)
Adult
(10)
Female
(9)
Respiratory System
(8)
Asthma
(6)
Biological And Medical Sciences
(6)
Double-Blind Method
(6)
Pharmacology & Pharmacy
(6)
Chronic Obstructive Pulmonary Disease
(5)
Medical Sciences
(5)
Middle Aged
(5)
Asthma - Drug Therapy
(4)
Cross-Over Studies
(4)
General & Internal Medicine
(4)
Inflammation
(4)
Lung Diseases
(4)
Medicine, General & Internal
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis

An exploratory study investigating biomarkers associated with autoimmune pulmonary alveolar proteinosis (aPAP)

Transcriptomic characterization of the human segmental endotoxin challenge model

Baseline characteristics from a 3-year longitudinal study to phenotype subjects with COPD: the FOOTPRINTS study

Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis

Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment

FOOTPRINTS study protocol: rationale and methodology of a 3-year longitudinal observational study to phenotype patients with COPD

A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf

An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CFTM 1

Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia

Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia

TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial

Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study

The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers

FEV1 recovery following methacholine challenge in asthma: Variability and comparison of methods

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well‐Controlled Asthma

A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma

COPDGene ® 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease

Anticipated responses to a hypothetical minimum price for cigarettes and roll-your-own tobacco: an online cross-sectional survey with cigarette smokers and ex-smokers in the UK

FEV 1 recovery following methacholine challenge in asthma: Variability and comparison of methods

An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CF TM 1

P38 mitogen activated protein kinase is involved in the downregulation of granulocyte CXC chemokine receptors 1 and 2 during human endotoxemia

Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis

Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist Bl 671800 in patients with seasonal allergic rhinitis

Drug-induced hypothyroidism: The thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides

Suchergebnisse filtern